npj Parkinson's Disease (Sep 2023)
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
- Clodagh Towns,
- Madeleine Richer,
- Simona Jasaityte,
- Eleanor J. Stafford,
- Julie Joubert,
- Tarek Antar,
- Alejandro Martinez-Carrasco,
- Mary B. Makarious,
- Bradford Casey,
- Dan Vitale,
- Kristin Levine,
- Hampton Leonard,
- Caroline B. Pantazis,
- Laurel A. Screven,
- Dena G. Hernandez,
- Claire E. Wegel,
- Justin Solle,
- Mike A. Nalls,
- Cornelis Blauwendraat,
- Andrew B. Singleton,
- Manuela M. X. Tan,
- Hirotaka Iwaki,
- Huw R. Morris,
- the Global Parkinson’s Genetics Program (GP2)
Affiliations
- Clodagh Towns
- Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
- Madeleine Richer
- Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
- Simona Jasaityte
- Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
- Eleanor J. Stafford
- Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
- Julie Joubert
- Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
- Tarek Antar
- Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health
- Alejandro Martinez-Carrasco
- Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
- Mary B. Makarious
- Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
- Bradford Casey
- Department of Clinical Research, Michael J. Fox Foundation for Parkinson’s Research
- Dan Vitale
- National Institutes of Health
- Kristin Levine
- Center for Alzheimer’s and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health
- Hampton Leonard
- Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health
- Caroline B. Pantazis
- National Institutes of Health
- Laurel A. Screven
- Center for Alzheimer’s and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health
- Dena G. Hernandez
- Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health
- Claire E. Wegel
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Justin Solle
- Department of Clinical Research, Michael J. Fox Foundation for Parkinson’s Research
- Mike A. Nalls
- Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health
- Cornelis Blauwendraat
- National Institutes of Health
- Andrew B. Singleton
- Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health
- Manuela M. X. Tan
- Department of Neurology, Oslo University Hospital
- Hirotaka Iwaki
- Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health
- Huw R. Morris
- Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London
- the Global Parkinson’s Genetics Program (GP2)
- DOI
- https://doi.org/10.1038/s41531-023-00533-w
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 6
Abstract
Abstract The Global Parkinson’s Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic and clinical data for use in large-scale analyses to dramatically expand our understanding of the genetic architecture of PD. This report details the workflow for cohort integration into the complex arm of GP2, and together with our outline of the monogenic hub in a companion paper, provides a generalizable blueprint for establishing large scale collaborative research consortia.
